کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8786227 | 1601129 | 2018 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
تومور شناسی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer](/preview/png/8786227.png)
چکیده انگلیسی
A strategy using accelerated hypofractionated 3DCRT is feasible and reasonably safe for patients with inoperable NSCLC. It is safe to deliver for centrally located tumours if DVCs are applied to the oesophagus, which is the primary dose-limiting toxicity. Further studies are required to assess the efficacy of hypofractionated regimens for centrally located tumours using an oesophageal DVC and monitoring for oesophageal toxicity.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Oncology - Volume 30, Issue 1, January 2018, Pages 30-38
Journal: Clinical Oncology - Volume 30, Issue 1, January 2018, Pages 30-38
نویسندگان
D.N. Cagney, P.G. Thirion, M.T. Dunne, C. Fleming, D. Fitzpatrick, C.M. O'Shea, M.A. Finn, S. O'Sullivan, C. Booth, C.D. Collins, S.J. Buckney, A. Shannon, J.G. Armstrong,